Who are AN2690 Solution, 5.0%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TEV-48125.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/an2690-solution-5-0.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

AN2690 Solution, 5.0% — Competitive Intelligence Brief

AN2690 Solution, 5.0% (AN2690 Solution, 5.0%) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sodium-activated potassium channel blocker. Area: Neurology.

phase 2 Sodium-activated potassium channel blocker KCNMA1 Neurology Small molecule Live · refreshed every 30 min

Target snapshot

AN2690 Solution, 5.0% (AN2690 Solution, 5.0%) — Pfizer. AN2690 Solution is a small molecule that acts as a selective and potent inhibitor of the sodium-activated potassium channel, KCNMA1.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AN2690 Solution, 5.0% TARGET	AN2690 Solution, 5.0%	Pfizer	phase 2	Sodium-activated potassium channel blocker	KCNMA1
TEV-48125	TEV-48125	Otsuka Pharmaceutical Co., Ltd.	phase 3	sodium-activated potassium channel blocker	Nav1.5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sodium-activated potassium channel blocker class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AN2690 Solution, 5.0% — Competitive Intelligence Brief. https://druglandscape.com/ci/an2690-solution-5-0. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab